Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
222
44
52
52
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.9%
2 terminated/withdrawn out of 222 trials
96.3%
+9.7% vs industry average
11%
25 trials in Phase 3/4
8%
4 of 52 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (222)
Hearing Intervention Effects on Brain and Language Development in Children With Bilateral Mild Hearing Loss
Role: lead
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Role: lead
Case Management for Microtia
Role: collaborator
Abiraterone With Dalpiciclib in Salivary Gland Carcinoma
Role: lead
PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis
Role: collaborator
The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
Role: collaborator
Discovery and Validation of Biomarkers for Periodontitis, Dental Caries and Oral Squamous Cell Carcinoma
Role: lead
Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis
Role: lead
Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis
Role: lead
Efficacy of Lymphatic-Venous Anastomosis Plus Donepezil Versus Donepezil Alone for Alzheimer's Disease
Role: lead
A Prospective Multicenter Cohort Study About Internal Fixation Using FNS Versus MCS for Femoral Neck Fracture
Role: collaborator
Acupuncture Versus Sham Acupuncture for Tinnitus
Role: lead
Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Role: lead
CLASSIFY-OMM: Multicenter Rare Disease Cohort for T-Stage Reclassification and Molecular Subtyping-Based Precision Therapy in Oral Mucosal Melanoma
Role: lead
Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies
Role: lead
Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC
Role: lead
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Role: lead
Iparomlimab and Tuvonralimab in HNSCC
Role: lead
Hidden Hearing Loss in Older Adults
Role: lead
Comparison of Accuracy of Full-arch Implant Digital and Conventional Impressions.
Role: lead